164 related articles for article (PubMed ID: 31977472)
1. Peptide Receptor Radionuclide Therapy Using 225Ac-DOTATOC Achieves Partial Remission in a Patient With Progressive Neuroendocrine Liver Metastases After Repeated β-Emitter Peptide Receptor Radionuclide Therapy.
Zhang J; Kulkarni HR; Baum RP
Clin Nucl Med; 2020 Mar; 45(3):241-243. PubMed ID: 31977472
[TBL] [Abstract][Full Text] [Related]
2. Intraarterial Peptide Receptor Radionuclide Therapy Using
Lawhn-Heath C; Fidelman N; Chee B; Jivan S; Armstrong E; Zhang L; Lindsay S; Bergsland EK; Hope TA
J Nucl Med; 2021 Feb; 62(2):221-227. PubMed ID: 32513903
[TBL] [Abstract][Full Text] [Related]
3. 225Ac-DOTATOC-Targeted Somatostatin Receptor α-Therapy in a Patient With Metastatic Neuroendocrine Tumor of the Thymus, Refractory to β-Radiation.
Zhang J; Kulkarni HR; Baum RP
Clin Nucl Med; 2021 Dec; 46(12):1030-1031. PubMed ID: 34238802
[TBL] [Abstract][Full Text] [Related]
4. ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience.
Kratochwil C; Giesel FL; Bruchertseifer F; Mier W; Apostolidis C; Boll R; Murphy K; Haberkorn U; Morgenstern A
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2106-19. PubMed ID: 25070685
[TBL] [Abstract][Full Text] [Related]
5. Ectopic Corticotropin-Producing Neuroendocrine Tumor of the Pancreas Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.
Makis W; McCann K; Riauka TA; McEwan AJ
Clin Nucl Med; 2016 Jan; 41(1):50-2. PubMed ID: 26359569
[TBL] [Abstract][Full Text] [Related]
6. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor.
Todorović-Tirnanić M; Kaemmerer D; Prasad V; Hommann M; Baum RP
Recent Results Cancer Res; 2013; 194():487-96. PubMed ID: 22918778
[TBL] [Abstract][Full Text] [Related]
7. Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting.
Kalshetty A; Ramaswamy A; Ostwal V; Basu S
Nucl Med Commun; 2018 Dec; 39(12):1143-1149. PubMed ID: 30308585
[TBL] [Abstract][Full Text] [Related]
8. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
9. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.
Krenning EP; de Jong M; Kooij PP; Breeman WA; Bakker WH; de Herder WW; van Eijck CH; Kwekkeboom DJ; Jamar F; Pauwels S; Valkema R
Ann Oncol; 1999; 10 Suppl 2():S23-9. PubMed ID: 10399029
[TBL] [Abstract][Full Text] [Related]
10. 177Lu-DOTATOC Peptide Receptor Radionuclide Therapy in a Patient With Neuroendocrine Breast Carcinoma and Breast Invasive Ductal Carcinoma.
Liu Q; Zhang J; Kulkarni HR; Baum RP
Clin Nucl Med; 2020 May; 45(5):e232-e235. PubMed ID: 32209879
[TBL] [Abstract][Full Text] [Related]
11. Sequential Duo-Peptide Receptor Radionuclide Therapy With Indigenous 90Y-DOTATATE and 177Lu-DOTATATE in Large-Volume Neuroendocrine Tumors: Posttherapy Bremsstrahlung and PET/CT Imaging Following 90Y-DOTATATE Treatment.
Parghane RV; Mitra A; Upadhye T; Rakshit S; Banerjee S; Basu S
Clin Nucl Med; 2020 Sep; 45(9):714-715. PubMed ID: 32657872
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors.
Miederer M; Henriksen G; Alke A; Mossbrugger I; Quintanilla-Martinez L; Senekowitsch-Schmidtke R; Essler M
Clin Cancer Res; 2008 Jun; 14(11):3555-61. PubMed ID: 18519789
[TBL] [Abstract][Full Text] [Related]
13. Peptide Receptor Radionuclide Therapy as First-Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumors.
Satapathy S; Mittal BR; Sood A; Sood A; Kapoor R; Gupta R
Clin Nucl Med; 2020 Sep; 45(9):e393-e399. PubMed ID: 32604121
[TBL] [Abstract][Full Text] [Related]
14. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study.
Braat AJAT; Bruijnen RCG; van Rooij R; Braat MNGJA; Wessels FJ; van Leeuwaarde RS; van Treijen MJC; de Herder WW; Hofland J; Tesselaar MET; de Jong HWAM; Lam MGEH
Lancet Oncol; 2020 Apr; 21(4):561-570. PubMed ID: 32112737
[TBL] [Abstract][Full Text] [Related]
15. Peptide receptor radionuclide therapy with
Magalhães D; Sampaio IL; Ferreira G; Bogalho P; Martins-Branco D; Santos R; Duarte H
J Endocrinol Invest; 2019 Mar; 42(3):249-260. PubMed ID: 29949120
[TBL] [Abstract][Full Text] [Related]
16. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?
Ezziddin S; Lohmar J; Yong-Hing CJ; Sabet A; Ahmadzadehfar H; Kukuk G; Biersack HJ; Guhlke S; Reichmann K
Clin Nucl Med; 2012 Jun; 37(6):e141-7. PubMed ID: 22614212
[TBL] [Abstract][Full Text] [Related]
17. Successful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3: A Somatostatin Receptor Antagonist.
Zhang J; Kulkarni HR; Singh A; Baum RP
Clin Nucl Med; 2020 Mar; 45(3):e165-e168. PubMed ID: 31977464
[TBL] [Abstract][Full Text] [Related]
18. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES
Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377
[TBL] [Abstract][Full Text] [Related]
19. Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement.
Sabet A; Khalaf F; Yong-Hing CJ; Sabet A; Haslerud T; Ahmadzadehfar H; Guhlke S; Grünwald F; Biersack HJ; Ezziddin S
Nuklearmedizin; 2014; 53(2):54-9. PubMed ID: 24777355
[TBL] [Abstract][Full Text] [Related]
20. Ectopic Corticotropin-Releasing Hormone-Secreting Pancreatic Neuroendocrine Tumor: Excellent Response of Liver Metastases to Peptide Receptor Radionuclide Therapy as Demonstrated by 68Ga-DOTATOC and 18F-FDG PET/CT Imaging.
Zhang J; Kulkarni HR; Baum RP
Clin Nucl Med; 2020 Feb; 45(2):e125-e127. PubMed ID: 31714276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
